290 related articles for article (PubMed ID: 29394118)
1. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
[TBL] [Abstract][Full Text] [Related]
2. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
3. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes.
Levasseur SD; Wittenberg LA; White VA
JAMA Ophthalmol; 2013 Jan; 131(1):50-5. PubMed ID: 23307208
[TBL] [Abstract][Full Text] [Related]
4. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Castellino A; Pulido JS; Johnston PB; Ristow KM; Nora Bennani N; Inwards DJ; Macon WR; Micallef INM; King RL; Salomao DR; Witzig TE; Habermann TM; Nowakowski GS
Am J Hematol; 2019 Mar; 94(3):291-298. PubMed ID: 30516868
[TBL] [Abstract][Full Text] [Related]
5. Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Porcu P; Martinez NL; Glass J; Mashayekhi A; Shields CL
Asia Pac J Ophthalmol (Phila); 2020; 9(2):110-116. PubMed ID: 31923035
[TBL] [Abstract][Full Text] [Related]
6. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
7. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
8. Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
Giuffrè C; Cicinelli MV; Marchese A; Modorati GM; Brambati M; Ferreri AJM; Calimeri T; Ponzoni M; Bandello F; Miserocchi E
Ocul Immunol Inflamm; 2021 Apr; 29(3):472-478. PubMed ID: 32845738
[No Abstract] [Full Text] [Related]
9. How we diagnose and treat vitreoretinal lymphoma.
Fend F; Ferreri AJ; Coupland SE
Br J Haematol; 2016 Jun; 173(5):680-92. PubMed ID: 27133587
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
11. An unusual case report of primary vitreoretinal lymphoma.
Tan SZ; Steeples LR; Chhabra R; Jones NP
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):223. PubMed ID: 30255824
[TBL] [Abstract][Full Text] [Related]
12. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
Kaburaki T; Taoka K
Jpn J Ophthalmol; 2023 Jul; 67(4):363-381. PubMed ID: 37209195
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma.
Ito T; Takeda A; Fujiwara K; Hasegawa E; Nakao S; Ohishi Y; Oda Y; Yoshikawa H; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):1029-1036. PubMed ID: 30868235
[TBL] [Abstract][Full Text] [Related]
16. DIFFERENTIAL DIAGNOSIS FOR VITREORETINAL LYMPHOMA WITH VITREORETINAL FINDINGS, IMMUNOGLOBULIN CLONALITY TESTS, AND INTERLEUKIN LEVELS.
Lee J; Kim SW; Kim H; Lee CS; Kim M; Lee SC
Retina; 2019 Jun; 39(6):1165-1176. PubMed ID: 29474309
[TBL] [Abstract][Full Text] [Related]
17. Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.
Abu Samra K; Oray M; Ebrahimiadib N; Lee S; Anesi S; Foster CS
Ocul Immunol Inflamm; 2018; 26(3):347-352. PubMed ID: 27438792
[TBL] [Abstract][Full Text] [Related]
18. Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze.
Marchese A; Miserocchi E; Giuffrè C; Cicinelli MV; Querques G; Bandello F; Modorati G
Br J Ophthalmol; 2019 Nov; 103(11):1656-1659. PubMed ID: 30709808
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
20. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature.
Gao S; Zhou Y; Jin X; Lin Z; Zhong Y; Shen X
Surv Ophthalmol; 2019; 64(2):225-232. PubMed ID: 30321569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
